Evidence map›Paper›PMID 41148678›Full record

ArticleAntibiotics (Basel, Switzerland)2025

Drug Resistance and Comorbidities in the Treatment of Pulmonary Tuberculosis: A Multicenter Retrospective Cohort Study.

Nikolay N Osipov, Dmitry Spelnikov, Ekaterina Belyaeva, Anastasia Kulpina, Mikhail Nazarenko, Gudkin Mikhail, Nikolay Yu Nikolenko, Dmitry Kudlay, Anna Starshinova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nikolay N OsipovDepartment of Mathematics and Computer Science, St. Petersburg State University, St. Petersburg 199034, Russia.ORCID 0000-0002-5391-3917
Dmitry SpelnikovDepartment of Mathematics and Computer Science, St. Petersburg State University, St. Petersburg 199034, Russia.
Ekaterina BelyaevaDepartment of Mathematics and Computer Science, St. Petersburg State University, St. Petersburg 199034, Russia.
Anastasia KulpinaDepartment of Mathematics and Computer Science, St. Petersburg State University, St. Petersburg 199034, Russia.
Mikhail NazarenkoSt. Petersburg Pushkin Antituberculosis Dispensary, St. Petersburg 196602, Russia.
Gudkin MikhailInterdistrict Petrogradsko-Primorsky Anti-Tuberculosis Dispensary N. 3, St. Petersburg 197343, Russia.
Nikolay Yu NikolenkoMoscow Research and Clinical Center for Tuberculosis Control, Moscow 107014, Russia.ORCID 0000-0002-1071-2680
Dmitry KudlayDepartment of Pharmacology, Institute of Pharmacy, M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Anna StarshinovaDepartment of Mathematics and Computer Science, St. Petersburg State University, St. Petersburg 199034, Russia.ORCID 0000-0002-9023-6986

Funding

the Ministry of Science and Higher Education of the Russian Federation 075-15-2025-013
6 · The paper itself

Abstract

Tuberculosis (TB) probably returned to being the world's leading cause of death from a single infectious agent after three years during which it was replaced by COVID-19. Currently, there are two major, closely related challenges in TB treatment: a large number of cases of drug-resistant TB, as well as cases complicated by severe comorbidities.

Indexed as

anti-tuberculosis drugsbedaquilinecardiotoxicitycomorbiditydrug-resistant tuberculosisextensive drug resistanceheard diseasethioamidesXDR-TB

Identifiers

PMID41148678
PMCPMC12562023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.